2-(2,5-dimethylphenoxy)-N-(2-hydroxy-5-methylphenyl)acetamide is a **synthetic compound** that has been investigated for its potential **biological activity**. Here's a breakdown of its structure and possible importance:
**Structure:**
* **2-(2,5-dimethylphenoxy):** This part of the molecule indicates a phenoxy group (an oxygen atom attached to a benzene ring) with two methyl groups attached to the benzene ring in positions 2 and 5.
* **Acetamide:** This part represents the basic structure of an amide, with a carbonyl group (C=O) connected to a nitrogen atom.
* **N-(2-hydroxy-5-methylphenyl):** This tells us that the nitrogen of the amide is linked to a 2-hydroxy-5-methylphenyl group, which is a phenol (an aromatic ring with a hydroxyl group) with a methyl group at position 5.
**Importance for Research:**
* **Potential Anti-Inflammatory Activity:** The presence of the phenoxy and phenolic groups, along with the amide structure, suggests that the molecule could potentially interact with various biological targets involved in inflammation. Further research is needed to confirm this.
* **Possible Antimicrobial Activity:** The compound might possess antimicrobial properties due to the presence of the aromatic rings and the potential for hydrogen bonding interactions with bacterial cell membranes.
* **Lead Compound for Drug Development:** If the compound shows promising biological activity in preclinical studies, it could act as a lead compound for the development of new drugs for inflammation, infections, or other conditions.
**Important Note:** The specific biological activity and potential applications of 2-(2,5-dimethylphenoxy)-N-(2-hydroxy-5-methylphenyl)acetamide require further investigation and validation through rigorous scientific research.
**To understand the compound's importance, consider these questions:**
* **Has the compound been tested for biological activity in laboratory settings?**
* **What specific biological targets does it interact with?**
* **Are there any known side effects or toxicity associated with this compound?**
**Researching the compound further:**
* **PubMed:** You can find relevant research papers on PubMed by searching for the compound's name or its structure.
* **Scientific Databases:** Use scientific databases like SciFinder, Reaxys, or PubChem to find information about its synthesis, properties, and biological activity.
Remember, research is an ongoing process, and it's always important to consult reliable scientific sources for the latest information and interpretation of research findings.
ID Source | ID |
---|---|
PubMed CID | 977208 |
CHEMBL ID | 1371372 |
CHEBI ID | 123379 |
Synonym |
---|
2-(2,5-dimethylphenoxy)-n-(2-hydroxy-5-methylphenyl)acetamide |
smr000075767 |
MLS000063852 , |
STK224528 |
SR-01000272871-3 |
CHEBI:123379 |
AKOS003318616 |
HMS2317I16 |
bdbm71820 |
2-(2,5-dimethylphenoxy)-n-(2-hydroxy-5-methyl-phenyl)acetamide |
2-(2,5-dimethylphenoxy)-n-(5-methyl-2-oxidanyl-phenyl)ethanamide |
cid_977208 |
CHEMBL1371372 |
Q27213089 |
sr-01000272871 |
SR-01000272871-1 |
Class | Description |
---|---|
anilide | Any aromatic amide obtained by acylation of aniline. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 79.4328 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.6228 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 79.4328 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 5.0119 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 8.1995 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 0.0501 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 21.1923 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Gli1 | Mus musculus (house mouse) | IC50 (µMol) | 3.3400 | 0.0270 | 4.2939 | 11.4000 | AID602464 |
protein Wnt-3a precursor | Mus musculus (house mouse) | IC50 (µMol) | 50.0000 | 0.4410 | 4.9952 | 14.8000 | AID651570 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 260.0000 | 0.1600 | 24.4900 | 236.5000 | AID435004 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |